Main > ONCOLOGY (**) > Breast Cancer>HER2+ *** > Adjuvant TREAT. > Co: USA. P. Neratinib

---

Co: USA. P. Neratinib's subsections
(*) AR Approval Date: 2019. 09.04
(*) EU Approval Date: 2018. 09.04
(*) USA Approval Date: 2017. 07.17
(*) USA Launch Date: 2017. 07.31
Company
Licensor
TradeMark
TradeMark Web-Site
Tyrosine Kinase Inhibitor

Co: USA. P. Neratinib's products
This section has no products